Variable | n* | Proportion (%) |
Total | 185 252 | 100 |
Age (mean±SD), years | 65.4±12 | |
Male | 122 881 | 66 |
1 year prior to the ASCVD onset | ||
Prior use of statins | 87 191 | 47 |
Prior lipid examination | 119 874 | 65 |
Comorbidity | ||
Charlson Comorbidity Index score (mean±SD) | 1.79±1.8 | |
Hyperlipidaemia | 81 655 | 44 |
Hypertension | 126 530 | 68 |
Ischaemic heart disease | 87 031 | 47 |
Diabetes | 76 390 | 41 |
COPD | 18 112 | 10 |
Prior use of other medications | ||
Antiplatelet | 119 947 | 65 |
CCB | 104 848 | 57 |
β blockers | 92 994 | 50 |
ARB | 72 550 | 39 |
OAD | 68 073 | 37 |
Baseline ASCVD hospitalisation | ||
Type of ASCVD diagnosis | ||
Ischaemic stroke | 74 753 | 40 |
Stable CHD receiving revascularisation | 67 779 | 37 |
AMI with PTCA/CABG | 33 021 | 18 |
AMI without PTCA/CABG | 9699 | 5 |
In-hospital statin use | 151 020 | 82 |
In-hospital lipid examination | 163 329 | 88 |
Index date statin prescription | ||
Healthcare institute accreditation level | ||
Medical centre | 95 326 | 51 |
Regional hospital | 58 111 | 31 |
District hospital | 17 129 | 9 |
Other hospital | 10 440 | 6 |
Clinic | 4246 | 2 |
Physician specialty | ||
Cardiovascular medicine | 96 018 | 52 |
Cardiovascular surgery | 7540 | 4 |
Neurology | 53 050 | 29 |
Metabolism and endocrinology | 7899 | 4 |
Internal medicine | 13 798 | 7 |
Family medicine | 2971 | 2 |
Others | 3976 | 2 |
*Except for the variables ‘age’ and ‘Charlson Comorbidity Index score’.
AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CABG, coronary artery bypass graft; CCB, calcium channel blocker; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disorder; OAD, oral antidiabetic drug; PTCA, percutaneous transluminal coronary angioplasty.